Cell Source's Megadose Drug Combination Receives Regulatory Approval in Italy to Commence Human Clinical Trials

Independent, 3rd Party Researchers at Italian University to Conduct Study

TEL AVIV, Israel, Nov. 13, 2014 /PRNewswire/ -- Cell Source, Inc. (OTCQB: CLCS) ("Cell Source") an immunotherapy and regenerative medicine company, announced today its Megadose Drug Combination has been cleared for human clinical trials in Italy. Cell Source's proprietary Megadose Drug Combination is expected to increase bone marrow transplantation (BMT) success and survival. By combining an established cell therapy with U.S. Food and Drug Administration (FDA) approved drugs, Megadose Drug Combination, based on preclinical results to date, may have the potential to enable an improvement in the effectiveness and safety of use of mismatched BMT. BMT is most often used for the treatment of blood cancers and is currently reserved mostly for patients with life threatening diseases, due to complications including transplant rejection. Should BMT become safer, the procedure's use may well be expanded beyond cancer to other indications including genetic and autoimmune disease.

A leading Italian university hospital with extensive BMT experience, an independent third party organization, has on its own initiative chosen to conduct a human clinical trial of Megadose Drug Combination on a self-directed basis. While Cell Source is not a sponsor of the trial, a positive outcome could be encouraging.

The Italian university filed an investigational new drug application (IND) with the Italian Medicine Association, the Italian equivalent of the U.S. FDA, to conduct human clinical trials using the Megadose Drug Combination in the first half of 2014. The Italian Medicine Association granted approval for the IND and commencement of the study with a small number of patients on October 23, 2014.

"We are very pleased that independent researchers at this Italian university have found our Megadose Drug Combination compelling enough to initiate their own study. The treatment protocol the university intends to implement for the study is the same protocol we intend to use in our own future Phase I/II study. Therefore, the data resulting from their study will be an important indicator for Cell Source's future trials and positive results would serve as an additional springboard," stated Cell Source President and CEO Itamar Shimrat.

In preclinical studies Megadose Drug Combination has shown success in inducing immune tolerance. The drug has shown to enable the coexistence of host and donor DNA, thus significantly reducing transplant rejection.

Cell Source is the exclusive worldwide licensee of a variety of progressive cell therapy technologies invented at the Weizmann Institute of Science, one of Israel's and the world's leading research institutes.

For further information, please visit www.cell-source.com or contact Itamar Shimrat, President and CEO (646) 416-7896.

About Cell Source, Inc.

Cell Source is an immunotherapy and regenerative medicine company whose primary breakthrough is the regulation of immune tolerance. In preclinical studies Cell Source's therapies have demonstrated the ability to directly address a number of severe medical conditions including blood cancers such as non-Hodgkins lymphoma, multiple myeloma, and chronic lymphocytic leukemia. Cell Source's organ regeneration platform holds the potential to repair organs and to grow entire organs inside the patient's body. Growing or regenerating organs and using cell therapy to tolerize the immune system can each revolutionize the treatment of numerous severe diseases that today kill hundreds of thousands of patients annually.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995

With the exception of historical information, the matters discussed in this news release are forward-looking statements that

involve a number of risks and uncertainties. The actual future results of Cell Source could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations, inability to hire and retain qualified personnel, and changes in the general economic climate. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by Cell Source, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

SOURCE Cell Source, Inc.